Background Artemisinin-based combinations are judged the best treatments for multidrug-resistant Plasmodium falciparum malaria. Artesunate-mefl oquine is widely recommended in southeast Asia, but its high cost and tolerability profi le remain obstacles to widespread deployment. To assess whether dihydroartemisinin-piperaquine is a suitable alternative to artesunate-mefl oquine, we compared the safety, tolerability, effi cacy, and eff ectiveness of the two regimens for the treatment of uncomplicated falciparum in western Myanmar (Burma).
Introduction
Resistance to antimalarial drugs has increased rapidly nearly everywhere in the tropics, and southeast Asia still has the most drug-resistant falciparum malaria in the world. [1] [2] [3] In Myanmar (Burma), chloroquine has been the fi rst-line treatment for falciparum malaria until recently. Studies in 1995 and 1998 by Médecins Sans Frontières (Holland), with the support of the Department of Health and the Vector Borne Disease Control Department, in the western and northern parts of the country showed very high rates of resistance to chloroquine and sulfadoxinepyrimethamine, the recommended treatments at the time. Mefl oquine monotherapy (15 mg/kg) had failure rates of 7% in Rakhine State, in the west of the country, 3 and 20% in Kachin State, in the north. 4 Thus, there was resistance to all available monotherapies. Combination therapy that includes an artemisinin derivative is now the preferred fi rst-line treatment for malaria.
In Myanmar, a 3-day treatment of mefl oquine and artesunate was highly effi cacious, even when the treatment was not fully supervised. 5 In September, 2002, the Myanmar Department of Health changed the national protocol for fi rst-line treatment of uncomplicated falciparum malaria to a 3-day artesunate-mefl oquine treatment (artesunate 12 mg/kg and mefl oquine 25 mg/kg). This change was an important step forward but there are several obstacles to implementing the policy. First, the high price of artesunate-mefl oquine (around US$3 for one adult treatment) means that this regimen is not accessible to most people with malaria, who are therefore still treated with chloroquine. Second, adverse eff ects are common after mefl oquine, and although most side-eff ects are not serious, they can lead to poor adherence with multiple-dose regimens. Third, mefl oquine and artesunate are not yet formulated in one tablet, so patients can take only the artesunate, thereby compromising effi cacy and encouraging resistance.
Two old drugs, dihydroartemisinin and piperaquine, have been formulated in a new combination treatment. Several studies in southeast Asia indicate that this combination is a safe and highly effi cacious treatment for uncomplicated multidrug-resistant falciparum malaria in adults and children. [6] [7] [8] [9] Compared with artesunate-mefl oquine, dihydroartemisinin-piperaquine has several potential advantages. First, it is cheaper (around US$1·50 for an adult treatment), which might improve access to eff ective antimalarial treatment for poor populations. Second, available data suggest that dihydroartemisinin-piperaquine is better tolerated than is artesunate-mefl oquine. 7 Third, the combination treatment is formulated in one tablet, which makes it easier to take, and should increase adherence and thereby limit the chance for selection of resistant parasites. Until recently, dihydroartemisinin-piperaquine was produced in the People's Republic of China and Vietnam, but the available products did not meet internationally accepted standards for good manufacturing practices.
In Myanmar, as in most countries, intake of antimalarial drugs is generally not supervised. Furthermore, treatment is unlikely to be supervised in the foreseeable future, with the exception of the fi rst dose, which can be given in the health clinic. Highly effi cacious treatments may not be eff ective if adherence to the prescribed treatment is poor. Adherence is related to the adverse-eff ect profi le. To assess this issue and inform policy we did a four-way randomised trial to compare the safety, tolerability, effi cacy, and eff ectiveness of dihydroartemisininpiperaquine with that of artesunate-mefl oquine for the treatment of uncomplicated falciparum malaria in adults and children in western Myanmar.
Methods

Study area and population
The study was done in two village-tracts, Dabhine and Mingan, which are about 10 km apart, in the township of Sittwe along the coast of the Bay of Bengal, in Rakhine State, western Myanmar. In this region, malaria transmission is seasonal (May-January) with peaks during the post-monsoon (November-January) and sometimes in the early monsoon (May-June) periods. The transmission intensity is geographically heterogeneous, varying from low to high over short distances. Plasmodium falciparum causes around 80% of the malaria infections that present to the clinics.
In 1994, Médecins Sans Frontières (Holland) started to support a malaria control programme in Rakhine State in cooperation with the Vector Borne Disease Control Department. The programme focuses on early diagnosis and treatment. Since 1996, all patients with falciparum malaria accessing this programme have been treated with a combination of mefl oquine and artesunate. The programme supports 30 fi xed clinics and three mobile malaria clinics, which visit remote areas by boat. In 2003, the programme provided a diagnostic test to 300 000 patients, of whom around 150 000 had falciparum malaria confi rmed and received a 3-day combination treatment with artesunate and mefl oquine (artesunate 12 mg/kg+mefl oquine 25 mg/kg). Our prospective study was done between November, 2003, and April, 2004.
If patients had fever (axillary temperature ≥37·5º C) or a history of fever within 48 h, a blood smear was prepared. Patients with confi rmed falciparum malaria were invited to take part in the study if they had more than 500 but fewer than 100 000 asexual parasites per μL, no clear signs or symptoms of other diseases, and no signs of severe or complicated malaria. Children younger than 1 year, pregnant women, patients with severe malaria, 10 patients with a history of taking mefl oquine in the previous 2 months or any other antimalarial drugs in the previous 48 h, and patients with a history of psychiatric diseases were excluded from the study. Patients with mixed infection (P falciparum with P vivax, P malariae, or both) were included. Patients who met the inclusion criteria were enrolled in the study only after fully informed consent was obtained from them or their carer. The protocol was approved by the Myanmar Department of Health and by the Médecins Sans Frontières ethics review board.
Procedures
Patients were stratifi ed prospectively into three age groups (1-4 years, 5-14 years, and older than 14 years) and allocated randomly to the four treatment regimens. At both study locations three boxes were prepared, one for each of the three age groups, by an administrator who was otherwise not connected with the study. In each box, 40 unmarked and sealed opaque envelopes were deposited. Each envelope contained a card that described the treatment assignment, and each treatment allocation had an equal number of cards (ten). Each new patient (or his or her carer) was asked to take one of the envelopes from the box for their age group. Treatment was then dispensed in accordance with the treatment allocation in the envelope. Whenever a box became empty, another 40 envelopes were put in that box.
All patients were examined clinically. A gametocyte count was done, blood was taken for measurement of the haemoglobin concentration, and a blood spot was taken on fi lter paper for PCR examination. Each PCR fi lter paper was dried, put in an individual plastic bag, and kept in an airtight box with silica gel.
This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN27914471.
Antimalarial drug regimens
The patients were randomly allocated to four treatment groups. The fi rst group was assigned supervised dihydroartemisinin-piperaquine (Artekin, Holleykin Pharmaceuticals, Guangzhou, China). The drug was given in a dose of 2·1 mg/kg dihydroartemisinin and 16·8 mg/kg piperaquine once daily for 3 days. Patients took every dose under supervision in the clinic. The number of pills was rounded off to the nearest half tablet. The usual adult dose was three tablets per day. The second group was assigned unsupervised dihydroartemisinin-piperaquine in the same doses as the fi rst group. The fi rst dose was supervised, but the treatments on days 1 and 2 were selfadministered at home. Group three was assigned 3-day treatment with mefl oquine (Lariam, Hoff man-La Roche, Basel, Switzerland) 25 mg base/kg single dose on day 0, and artesunate (Guilin Pharmaceutical Factory, Guilin, China) 4 mg/kg on days 0, 1, and 2. Every dose was given under supervision in the clinic. The number of pills was rounded off to the nearest quarter of a tablet. The usual adult dose was fi ve tablets of mefl oquine in one dose, and four tablets of artesunate per day. The fourth group was assigned the same drugs and the same doses as group three, but with the fi rst dose supervised and the treatments on day 1 and day 2 self-administered.
The diff erences in drug formulations meant that masking of treatment at the point of administration was not possible. For the drugs that were to be selfadministered in treatment groups 2 and 4 on days 1 and 2, two stapled small plastic bags were provided, marked 1 and 2, with the medication for the next 2 days. The importance of taking these drugs, even if symptoms had already subsided, was explained twice. All other antimalarial drug doses were given under the supervision of a treatment observer for 1 h. For children, tablets were crushed and syrup was added. If the patient vomited within 30 min, the full dose was repeated. Patients who vomited between 30 min and 60 min after drug administration were given half the initial dose. If the patient vomited the drugs twice, he or she was withdrawn from the study. For patients who vomited after 1 h, no repeat treatment was given and the patient remained in the study. Patients from treatment groups 1 and 3 were asked to return to the clinic on the next 2 days for supervised doses. Patients in these groups who missed doses in the mornings of days 1 and 2 were traced within 24 h, and the drugs were given under direct supervision. Patients from the unsupervised treatment groups (2 and 4) were asked to come back if they vomited within 1 h of drug administration.
Patients were requested to come back routinely on days 1 and 2 (only for the supervised treatment groups 1 and 3) and on days 7, 14, 21, 28, 35, and 42 after starting treatment (for all treatment groups) and at any other time when they felt unwell or thought they had fever. At each routine visit, a blood fi lm was taken for the identifi cation of malaria parasites, a gametocyte count was done, and a questionnaire was completed (for patients 4 years of age or older) to document sideeff ects. On day 7, the questionnaire for side-eff ects was detailed retrospectively for each day of the week (days 3-7 for groups 1 and 3, and days 1-7 for groups 2 and 4). Additionally, one blood sample (100 μL taken by micropipette) was kept on a fi lter paper on day 7, which was used later for the measurement of the blood concentration of piperaquine. On day 28, a blood sample was obtained for repeat haemoglobin measurement.
Repeat treatment was provided to patients who deteriorated clinically at any time, and those who returned on days 2-6 with patent P falciparum parasitaemia of more than 25% of the count on day 0. Patients who had persistent parasitaemia on days 2-6 but less than 25% of the initial parasite count and fever (but no clinical deterioration) were not defi ned as having treatment failure. These patients were followed up closely to ensure that no further deterioration took place. Repeat treatment was also provided to patients with P falciparum parasites on day 7 or any subsequent day.
For patients treated previously with dihydroartemisininpiperaquine the repeat treatment was with artesunatemefl oquine if there was no contraindication, and for patients who received artesunate-mefl oquine previously it was dihydroartemisinin-piperaquine. Mode of administration (supervised or not) was the same as for the initial treatment. Patients with treatment failure were followed up in the same way as those whose fi rst treatments had failed.
From all patients whose treatment failed, additional blood was obtained on a fi lter paper for PCR genotyping. Patients with a positive blood smear for P vivax, P ovale, or P malariae were not defi ned as having treatment failure. They were given chloroquine (25 mg base per kg during 3 days) and follow-up was continued.
To distinguish recrudescences from new infections, parasite genotypes were established on admission and in cases of recurrent parasitaemia. Parasite genotyping was done with PCR for variable blocks within MSP1, MSP2, and GLURP as described previously. 11 If a defi nitive statement could not be made, the outcome was recorded as indeterminate. Treatment failure rates were calculated for patients with proven recrudescences only and for patients with recrudescences or indeterminate PCR outcomes. The primary outcome measure was the rate of recrudescence confi rmed with PCR.
Piperaquine whole-blood concentrations were measured by solid-phase extraction and liquid chromatography. 12 The blood spots were cut into pieces and extracted with perchloric acid, phosphate buff er pH 2 containing internal standard, and acetonitrile for 1 h. The supernatants were loaded onto an MPC solid-phase extraction column (3M Empore, Bracknell, UK); the eluates were evaporated, reconstituted, and injected into a liquid chromatography system with a Chromolith performance column (VWR International, Darmstadt, Germany) and a mobile phase containing acetonitrile-phosphate buff er pH 2·5 0·1 mol/L (8:92 by volume) at a fl ow rate of 3 mL/min. The total precision for all quality controls during the analysis was 11·5% at 0·2 μg/mL, 10·9% at 0·75 μg/mL, and 7·4% at 2·5 μg/mL.
Statistical analysis
This trial was designed as a non-inferiority study. With a sample size of 160 patients in the four study groups, a cure rate of 95% with either drug regimen could be estimated with 5% precision, and a maximum allowable inferiority of 10% for dihydroartemisinin-piperaquine compared with artesunate-mefl oquine could be detected with 90% power and 95% confi dence, taking into account a withdrawal rate of up to 20%. Data were analysed with SPSS for Windows version 11.5, STATA version 9, and EpiInfo version 6. Continuous data were analysed by Student's t test or ANOVA, and proportions of categorical data were compared by χ 2 test with Yates' correction or a two-tailed Fisher's exact test. Comparisons between treatment groups were done in a two-way factor analysis: ANOVA for continuous data and multiple logistic regression model for categorical data. The eff ect of the treatment on recurrence of falciparum malaria was summarised by the risk diff erence. Eff ects of the treatment on other secondary outcomes were summarised by relative risks.
As a measure of transmission potential, we calculated the person-gametocyte-weeks, which were defi ned as the number of weeks in which blood slides were positive for gametocytes during the fi rst 2 weeks of follow-up after treatment divided by the number of weeks followed up, and were expressed per 1000 person-weeks. 13 Failure rates were estimated by survival analysis with the KaplanMeier method. Patients who did not complete follow-up or had a new infection were censored at the time they were last seen.
CIs around failure rate estimates were calculated by Greenwood's formula. When failure rates were zero, CIs were calculated by the exact binomial method with the eff ective sample sizes.
14 Equivalence between treatment groups was assessed by calculating the diff erences between failure rates and the CIs around these diff erences. CIs were based on the eff ective sample sizes as above and calculated with the Score method. 15 Recurrences that were indeterminate on the PCR analysis were treated fi rstly as censored observations and secondly as failures (to describe the worst-case scenario).
Role of the funding source
The sponsors of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Between November, 2003, and February, 2004, 15 228 patients were screened, but 14 576 were not eligible (fi gure 1). 1261 refused consent, mostly because they lived far from the clinic and because part of the study period was during Ramadan, which made it diffi cult for patients to comply with the follow-up requirements.
652 people met the inclusion criteria and were recruited for the study. Of them, 156 were assigned dihydroartemisinin-piperaquine (supervised), 171 dihydro artemisinin-piperaquine (home), 162 artesunate- (table 1) , with the exception of gametocytaemia on admission.
One 11-year-old child died during the study. He had received dihydroartemisinin-piperaquine (not super vised). During the follow-up visits on days 7 and 14, he had no fever and the blood smears were negative for malaria parasites. On the evening of day 20, the child developed fever. The next morning he had generalised seizures and his parents took him to the local hospital. The hospital physician noted decreased consciousness but no signs of meningism. A blood smear for malaria parasites was negative. The physician treated for cerebral malaria and bacterial meningitis with a loading dose of quinine, intravenous penicillin, and chloramphenicol. Nevertheless, the child died the next day. No autopsy was done.
16 other patients (2·5%) did not complete the 42 day follow-up period (fi gure 1). These patients were included in the data analysis for the period they participated.
Early responses to treatment could be measured only in the supervised-treatment groups, who returned to the clinic on days 1 and 2. Of these patients, the proportions whose parasitaemia had cleared after 1 day were 53% (82 of 155) after dihydroartemisinin-piperaquine and 45% (73 of 161) after artesunate-mefl oquine (relative risk 1·17 [95% CI 0·93-1·46], p=0·22). After 2 days the proportions of patients who had cleared parasitaemia were 97% (151 of 155) after dihydroartemisinin-piperaquine and 94% (150 of 159) after artesunate-mefl oquine, respectively. Of the remaining nine infections in the latter group, eight were P falciparum and one P vivax.
At baseline, 44% of patients in each supervised group were febrile (table 1). 1 day after treatment these proportions had dropped to 3% in both treatment groups (four of 155 and four of 161, respectively). All patients had clearance of their parasites by day 7.
Only seven patients had reappearance of parasites within 42 days, one after artesunate-mefl oquine (supervised) and six after dihydroartemisinin-piperaquine (four supervised, and two unsupervised). The relative risk for recurrent parasitaemia for dihydroartemisininpiperaquine versus artesunate-mefl oquine was 5·96 (0·72-49·26, p=0·12) . Two patients presented with fever, whereas the other fi ve were asymptomatic. Of the seven patients with recurrent parasitaemias, all were aged between 3 years and 6 years. Parasite genotyping was done on paired samples. In three patients a new genotype was confi rmed, indicating a new infection (all 28 days after supervised dihydroartemisinin-piperaquine). In two patients, recrudescent parasitaemias were confi rmed (one patient 14 days after dihydroartemisinin-piperaquine [home] and one patient 28 days after dihydroartemisininpiperaquine [supervised]). Of the two remaining patients, the PCR results were indeterminate (one patient 28 days after dihydroartemisinin-piperaquine [supervised] and one patient 35 days after artesunate-mefl oquine [supervised] ). If recurrences of parasitaemias that were indeterminate on the PCR analysis were treated as censored fi ndings, the failure rate was 0·6% (95% CI 0·2-2·5) for dihydroartemisinin-piperaquine and 0 (0-1·2) for artesunate-mefl oquine, and the diff erence between the two treatment groups was 0·63% (-0·66 to 2·28, p=0·16). However, if we assume that the PCR-indeterminate recurrences were treatment failures (the worst-case scenario), the failure rate was 0·9% (0·3-2·9) for dihydroartemisinin-piperaquine and 0·3% (0-2·2) for artesunate-mefl oquine, and the diff erence between the two treatment groups was 0·63% (-0·94 to 2·46). The four treatment groups were therefore regarded as therapeutically equivalent because all CI for diff erences were well within the 10% limits.
At baseline, 87 patients had mixed infections with P vivax (85 children and two adults). On day 7, all P vivax infections had cleared but 97 patients had presumed (table 1) . The proportions with gametocytaemia diff ered between the treatment groups despite randomisation, with higher proportions of gametocytaemia in the dihydroartemisinin-piperaquine groups than in the artesunate-mefl oquine groups (table 1) . The gametocyte carrier rate was higher in young children (85 of 159, 54%) than in older children (131 of 380, 35%) or adults (24 of 113, 21%; p<0·0001; table 3). There was a strong association between anaemia and gametocyte carriage. The proportion with patent gametocytaemia at baseline was highest in patients with haemoglobin concentration less than 80 g/L (35 of 78, 45%); 25% (26 of 110) of patients with haemoglobin of 80-100 g/L, and 19% (24 of 128) of those with haemoglobin more than 100 g/L, had gametocytaemia at baseline. In a stepwise multiple regression model both haemoglobin concentration and age were independently correlated with gametocytaemia (haemoglobin p<0·0001, and age p=0·008)
In the weeks after treatment, the gametocyte carriage rate decreased gradually and gametocytes were cleared by day 21 for both artesunate-mefl oquine groups, day 35 for the dihydroartemisinin-piperaquine (home) group, and day 42 for the dihydroartemisinin-piperaquine (supervised) group (table 4, fi gure 2). New gametocytaemia was also more common in the dihydroartemisinin-piperaquine groups than in the artesunate-mefl oquine groups on day 7 ( The mean haemoglobin concentration at baseline did not diff er in the four treatment groups, and 25% of patients had severe anaemia (haemoglobin <80g/L; table 1). On day 28, this proportion had decreased to 10% (64 of 631). The mean increases in haemoglobin did not diff er across the groups (p=0·36, table 5). Haemoglobin concentrations were lower in young children (mean 83 g/L) than in older children (93 g/L) and adults (112 g/L). The mean haemoglobin concentrations increased to 95 g/L, 102 g/L, and 113 g/L, respectively, for the three age groups by day 28. The increase in haemoglobin concentrations was signifi cantly greater for the younger groups (p<0·0001).
Adverse eff ects were reported most frequently in the fi rst week and were more commonly reported by patients in the supervised treatment groups than the nonsupervised groups (table 6). All patients were observed for 1 h after treatment on day 0. Overall 15 patients (2·3%) vomited within that time. On day 1, treatment was monitored only for the supervised groups. In these groups, eight patients vomited within 1 h (four in each drug group). On day 2, only two patients vomited, both from the dihydroartemisinin-piperaquine group. The patients in the non-supervised groups came back for the fi rst time on day 7. None reported vomiting within 1 h of taking the medicines on days 1 or 2. Thus, vomiting within 1 h was signifi cantly more common in the supervised than in the unsupervised groups (ten of 635 observations vs none of 668, p=0·0007). Vomiting on day 0 within 1 h of drug administration was more common in young children (ten of 159) than in older children (four of 386) and adults (one of 113, p=0·001).
Dizziness was the most frequently reported complaint. In the supervised groups, the proportion of patients reporting dizziness within 24 h of taking the tablets was signifi cantly smaller for the dihydroartemisininpiperaquine group than for the artesunate-mefl oquine group (47 of 133, 35% vs 72 of 151, 48%; relative risk 0·74
[0·56-0·98], p=0·05). There was a similar pattern for the dihydroartemisinin-piperaquine (home) and artesunatemefl oquine (home) groups (38 of 144, 26% vs 55 of 138, 40%; 0·66 [0·47-0·93], p=0·02). The next day the frequencies of dizziness had decreased. Dizziness was again reported less in the dihydroartemisinin-piperaquine groups than the artesunate-mefl oquine groups but these diff erences were not signifi cant: 18% (24 of 134) after supervised dihydroartemisinin-piperaquine and 27% (41 of 150) after supervised artesunate-mefl oquine (0·66 [0·42-1·02], p=0·08); and 19% (28 of 144) after dihydroartemisinin-piperaquine treatment at home and 28% (38 of 138) after artesunate-mefl oquine at home (0·71 [0·46-1·08], p=0·14). After day 2 the proportion reporting dizziness was 3% or less for all groups.
Nausea was also less frequently reported within 24 h of taking the tablets in the dihydroartemisinin-piperaquine (supervised) group than in the artesunate-mefl oquine dihydroartemisinin-piperaquine and 7% (ten of 138) after artesunate-mefl oquine (1·03 [0·44-2·39], p=0·87). On day 3, only one patient reported nausea. Adults reported signifi cantly more dizziness (p<0·0001) and nausea (p=0·0002) than children in the fi rst week.
Other side-eff ects such as anorexia, diarrhoea, itchiness, abdominal pain, and fatigue were less common, and their occurrence was not linked to the specifi c treatment groups. In the dihydroartemisinin-piperaquine group, three patients reported mild itching; two on day 0 and Continuous data were analysed by two-way ANOVA and proportions of categorical data were compared with multiple logistic regression model. p values adjusted for eff ect of supervision (supervised vs home). *Haemoglobin <100g/L. †Eff ect of the treatment diff ered for supervised group and home treated groups (p=0·03). The median blood piperaquine concentration on day 7 was 63 ng/mL (IQR 49-86; n=299); 28 samples were unavailable because of instrument failure. The concentrations were similar for the supervised (median 62 ng/mL [50-82]; mean 72 ng/mL) and home treatment groups (median 66 ng/mL [47-90 ng/mL]; mean 74 ng/mL; p=0·66 for comparison of medians; fi gure 3). Six patients had piperaquine concentrations lower than the limit of quantifi cation (25 ng/mL), of whom two had treatment failure (one recrudescent and one indeterminate). Five of six patients with piperaquine concen trations lower than the limit of quantifi cation were in the unsupervised group. Blood concentrations below the limit of quantifi cation were treated as zero and included in the analysis. The mean blood piperaquine concentration at day 7 was signifi cantly higher in the 293 patients who were successfully treated than in six with recrudescence or reinfection (74 [SD 39] ng/mL vs 34 [31] ng/mL, p=0·013).
Discussion
Both artesunate-mefl oquine and dihydroartemisininpiperaquine were highly effi cacious, eff ective, and welltolerated treatments for uncomplicated falciparum malaria in western Myanmar. Similar high cure rates have been reported previously in studies in Vietnam 7 (56-day cure rate 98·7%), Cambodia 8 (28-day cure rate 96·9%), and Thailand 9 (63-day cure rate 96·1%). Under normal conditions, without supervision of dosing after the initial consultation, cure rates were almost 100%. Since the effi cacy of incomplete regimens in these 3-day treatments is reduced, this rate suggests that nearly all patients completed their treatment as advised. In the case of artesunate-mefl oquine, all the mefl oquine and the fi rst dose of artesunate were given under supervision on the fi rst day, and in a previous study, this regimen (ie, 1-day treatment) was associated with a high (96·4%) cure rate. 5 But for dihydroartemisinin-piperaquine, a third of the dose (fi rst-day treatment only) is certainly not enough to account for such high cure rates, so adherence was probably good. This assumption is lent support by the whole-blood piperaquine results, which indicated little diff erence between the supervised and non-supervised groups.
The artesunate-mefl oquine combination, which has been the national protocol for falciparum malaria in Myanmar since 2002, has been used continuously since 1996 in this area. The treatment has retained a high cure rate, and the fact that there has been no selection of resistance evident in this region of western Myanmar over the past 7 years is encouraging. In Thailand, resistance to mefl oquine monotherapy arose within 7 years, but resistance to mefl oquine after deployment of the combination threatment has fallen. 16 These results, indicating good adherence to prescribed regimens and sustained high effi cacy, augur well for more general deployment of these artemisinin-based combinations. Mefl oquine is associated with predictable gastrointestinal and CNS adverse eff ects. In previous studies, tolerability and drug absorption were both increased by splitting the 25 mg/kg dose. In this study, the 3-day artesunatemefl oquine combination treatment was started with 25 mg/kg mefl oquine on day 0, by contrast with a previous study we did in the same region in which mefl oquine was divided over day 1 (15 mg/kg) and day 2 (10 mg/kg). This approach aimed to reduce the eff ects of poor adherence, which was thought to be more of a concern than reduced oral bioavailability. Indeed, cure rates were better in this study (no recrudescences in 159 patients) than in our earlier trial when mefl oquine was taken over days 1 and 2 (seven recrudescences of 180; 4%; p=0·016). This fi nding corroborates our previous suggestion 5 that, if the treatment cannot be supervised, and the tablets are separate, the whole dose of mefl oquine should be given on day 0 to ensure that it is taken, even though the drug's absorption and bioavailability might be less when taken as a single dose on day 0. 17 Vomiting of antimalarial drugs is an important consideration in treatment. Early vomiting occurred in only 2% of patients treated on the fi rst day with 25 mg/kg mefl oquine. This proportion is lower than reported previously. 18 Dihydroartemisinin-piperaquine treatment was associated with a similarly low frequency of early vomiting (2%) but had signifi cantly fewer other side-eff ects (dizziness and nausea), particularly in the fi rst 2 days. Vomiting on the next 2 days of treatment in supervised patients was infrequent and was not a major drawback in this study. The patients who took their medicines at home did not report any vomiting within 1 h after drug intake at all whereas in the supervised group some patients had early vomiting, although this reaction was mainly after the fi rst dose when febrile and ill. Thus, we think that some patients in the non-supervised group might have vomited on days 1 and 2, but that this reaction was not reported. If so, and since they did not request extra medicines, they would have had an inadequate dose and cure rates might have been expected to fall. Alternatively, when partly recovered and in the familiar setting of home, vomiting might be less likely. Patients should be informed clearly that in case of vomiting, extra tablets should be obtained. This factor is particularly important with dihydroartemisinin-piperaquine, since a third of the dose (fi rst day treatment only) is unlikely to be enough to cure the infection. During follow-up, patients who received dihydroartemisinin-piperaquine had fewer vivax infections, though not signifi cantly (p=0·07), but had signifi cantly more gametocyte carriage and more new gametocyte appearances.
Although the proportion of gametocytaemia at baseline, by chance, was higher in the dihydroartemisininpiperaquine group, the rate of new appearance of gametocytaemia was also signifi cantly higher in this group than in the artesunate-mefl oquine recipients. If the higher gametocyte carriage rate after dihydro artemisininpiperaquine is confi rmed, it would represent a publichealth disadvantage because it would indicate increased transmissibility. The higher gametocyte carriage rate might result from the lower dose of artemisinin derivative used in the dihydroartemisinin-piperaquine combination. This eff ect should be balanced against the advantages of simplicity of dosing, very high effi cacy and eff ectiveness, and an excellent adverse-eff ect profi le. Vivax malaria commonly followed falciparum malaria; indeed P vivax was by far the most common cause of malaria during the 6-week follow-up. Mixed infections are much more frequent than recognised from admission blood smears. 19 The appearance of P vivax infection after an eff ective treatment presumably represents a relapse. These infections were particularly frequent (40%) in children under 5 years of age. 20 Both health providers and parents in this area need to be informed that there is a high risk of another malaria episode in young children, and parents should be encouraged to bring the children to the clinic if fever reappears.
Although the question of adherence to antimalarial drugs is much debated, there are no defi nitions or guidelines to interpret incomplete adherence and few studies that have tried to measure it. A recent review identifi ed only 16 trials with widely diff ering methodologies. 21 The use of blood concentration measurements to assess adherence is facilitated by the availability of simple but sensitive validated fi lter-paper assay methods such as that for piperaquine. This method indicated generally excellent adherence to dihydroartemisininpiperaquine in our study, although the day 7 whole-blood piperaquine concentrations for the patients with treatment failure were lower than those for successfully treated patients, suggesting that the terminal elimination phase of piperaquine is an important determinant of effi cacy. 22 The fact that treatment success was high in this large study even when two-thirds of the treatment doses were not supervised is important because-in practice-most antimalarial treatments are taken at home. However, since the drugs were given free (whereas people generally have to pay), operational eff ectiveness might diff er from that presented here. Education of patients and price subsidy are both likely to be important in ensuring good adherence to the prescribed regimens under normal conditions of use. 23 In our setting, if the fi rst dose is supervised and a clear instruction is provided to the patient or carer, the eff ectiveness of the treatment equals its observed effi cacy. This study shows that both combination treatment regimens are eff ective, even when self-administered. Dihydroartemisinin-piperaquine is a good alternative for artesunate-mefl oquine because it is less expensive, coformulated, and has fewer side-eff ects. Dihydroartemisinin-piperaquine has the poten tial to play an important part in future malaria manage ment.
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